Briquilimab Biosimilar - Research Grade

Human

KIT

>1mg/ml

IgG1 - kappa

CHO Cells

Barzolvolimab Biosimilar - Research Grade (ICH5374), Eglatoprutug Biosimilar - Research Grade (ICH5510), Opelkibart Biosimilar - Research Grade (ICH5737)

https://www.imgt.org/mAb-DB/

ICH3002

P10721

3815

Blue ice

This product is a research-grade biosimilar of briquilimab, supplied as an unconjugated, non-therapeutic analog of the originator antibody and intended strictly for research use. It is built around the target biology of briquilimab, a humanized IgG1-kappa monoclonal antibody directed against human KIT (CD117), the receptor tyrosine kinase for stem cell factor. The originator is being developed as a conditioning and cell-depleting agent, notably to clear hematopoietic stem cells and mast cells in settings such as transplant conditioning, chronic urticaria, and related mast-cell and stem-cell-driven diseases, offering an antibody-based alternative to cytotoxic or radiation conditioning. As a biosimilar reagent, this molecule reproduces the target specificity of the clinical antibody without being a clinical drug and carries no clone designation. It is manufactured to research-grade endotoxin specifications (typically under 1 EU/mg) and is available in bulk milligram-to-gram quantities, making it suitable as a functional analog and reference material for in-vitro characterization, comparability, and control experiments. It is not intended for diagnostic or therapeutic use in humans or animals. KIT (CD117, encoded by the KIT proto-oncogene; UniProt P10721) is a type III receptor tyrosine kinase and the receptor for stem cell factor (SCF, KIT ligand). SCF binding drives receptor dimerization, autophosphorylation, and downstream signaling through PI3K/AKT, RAS/MAPK, and JAK/STAT pathways. KIT signaling is essential for the survival, proliferation, and differentiation of hematopoietic stem and progenitor cells, mast cells, melanocytes, germ cells, and interstitial cells of Cajal. Because hematopoietic stem cells and mast cells depend on KIT for maintenance, blocking the SCF-KIT axis can deplete or condition these populations. Activating KIT mutations drive gastrointestinal stromal tumors, systemic mastocytosis, and some acute myeloid leukemias, making KIT an important oncology and immunology target. Antibodies against KIT are studied as non-genotoxic conditioning and mast-cell-directed agents.

SCFR, Piebald trait protein, PBT, Proto-oncogene c-Kit, Tyrosine-protein kinase Kit, p145 c-kit, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, Mast/stem cell growth factor receptor Kit

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Briquilimab (anti-KIT) Biosimilar

Q: Is the Briquilimab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Briquilimab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Briquilimab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Briquilimab that binds KIT; for research use only.